Comparative Pharmacology
Head-to-head clinical analysis: ASBRON versus THEOCLEAR L A 130.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASBRON versus THEOCLEAR L A 130.
ASBRON vs THEOCLEAR L.A.-130
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Asbron is a combination product containing theophylline and guaifenesin. Theophylline is a methylxanthine that inhibits phosphodiesterase, leading to increased intracellular cAMP levels, resulting in bronchodilation and anti-inflammatory effects. Guaifenesin is an expectorant that increases respiratory tract fluid secretions to reduce mucus viscosity.
Theophylline is a methylxanthine that inhibits phosphodiesterase, increasing intracellular cAMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
1-2 tablets (130-260 mg theophylline equivalent) orally every 6-8 hours; maximum 6 tablets/day.
130 mg orally every 12 hours; extended-release tablet.
None Documented
None Documented
4-6 hours in adults; prolonged to 8-12 hours in hepatic impairment or elderly patients
Terminal elimination half-life is 3-8 hours in healthy adults (mean 5-6 hours). It is prolonged in patients with hepatic cirrhosis, heart failure, or COPD (up to 30 hours) and in neonates (20-30 hours). Smoking induces metabolism, reducing half-life to 1-4 hours.
Primarily renal (70-80% as unchanged drug), biliary/fecal (~15-20% as metabolites and unchanged drug)
Approximately 90% of theophylline is eliminated hepatically via CYP1A2 and CYP3A4 metabolism; renal excretion of unchanged drug accounts for about 10% in adults, but may increase to 50% in neonates. Biliary/fecal elimination is negligible.
Category C
Category C
Bronchodilator
Bronchodilator